Delivery and performance of surfactant replacement therapies to treat pulmonary disorders

Therapeutic Delivery

Volumn 4, Issue 8, 2013, Pages 951-980

  El Gendy, Nashwa ^a,b   Kaviratna, Anubhav ^c   Berkland, Cory ^a,c   Dhar, Prajnaparamita ^c  

^a UNIVERSITY OF KANSAS   (United States)

^b Beni Suef University   (Egypt)

^c University of Kansas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOSURF; ARTIFICIAL LUNG SURFACTANT; ATOVAQUONE; BERACTANT; BETAMETHASONE; BLES; CALFACTANT; CHF 5633; DEXAMETHASONE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; LUCINACTANT; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; LUSUPULTIDE; MINI B; PENTAMIDINE; PORACTANT; PUMACTANT; RECOMBINANT SURFACTANT PROTEIN A; RECOMBINANT SURFACTANT PROTEIN B; RECOMBINANT SURFACTANT PROTEIN D; TOBRAMYCIN; TURFSURF; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ACUTE RESPIRATORY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; CHRONIC LUNG DISEASE; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG INSTILLATION; DRUG MEGADOSE; DRY POWDER INHALER; ENDOSCOPY; EXTUBATION; HUMAN; INTUBATION; KLEBSIELLA PNEUMONIAE INFECTION; LARYNGEAL MASK; LOW DRUG DOSE; LUNG ALVEOLUS PROTEINOSIS; LUNG DISEASE; LUNG DYSPLASIA; LUNG HEMORRHAGE; MECONIUM ASPIRATION; MOLECULAR DYNAMICS; NASOGASTRIC TUBE; NEBULIZATION; NEBULIZER; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; PHARYNX; PNEUMOCYSTIS PNEUMONIA; PRENATAL PERIOD; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; REVIEW; SINGLE DRUG DOSE; SUBSTITUTION THERAPY; ULTRASOUND; VENTILATED PATIENT; VIRAL RESPIRATORY TRACT INFECTION;

EID: 84881534903     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.72     Document Type: Review

References (190)

1. Zasadzinski JA, Stenger PC, Shieh I, Dhar P. Overcoming rapid inactivation of lung surfactant: analogies between competitive adsorption and colloid stability. Biochim. Biophys. Acta 1798(4), 801-828 (2010).
2. Notter RH. Introduction to surface tension and surfactants. Lung surfactants: basic science and clinical applications, volume 149. Lenfant C (Ed.). Marcel Dekker, NY, USA, 7-39 (2000).
3. Zasadzinski J, Ding J, Warriner H, Bringezu F, Waring AJ. The physics and physiology of lung surfactants. Curr. Opin. Colloid Interface Sci. 6(5), 506-513 (2001).
4. Gower WA, Nogee LM. Surfactant dysfunction. Paediatr. Respir. Rev. 12(4), 223-229 (2011).
5. Kaviratna A, Banerjee R, Singh Rao S, Shah A. Pulmonary surfactant nanostructures and their implications. Dyn. Biochem. Process. Biotechnol. Mol. Biol. 3, 21-32 (2009).
6. Nkadi PO, Merritt TA, Pillers D-AM. An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease. Mol. Genet. Metab. 97(2), 95-101 (2009).
7. Hallman M, Glumoff V, Ramet M. Surfactant in respiratory distress syndrome and lung injury. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 129(1), 287-294 (2001).
8. Blanco O, Pérez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient pulmonary surfactant. Eur. J. Pharmacol. 568(1), 1-15 (2007).
9. Saxena S. Lung surfactant.Resonance 10(8), 91-96 (2005).
10. Frerking I, Günther A, Seeger W, Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med. 27(11), 1699-1717 (2001).
11. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Engl. J. Med. 344(8), 573-579 (2001).
12. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N. Engl. J. Med. 350(13), 1296-1303 (2004).
13. Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. Pediatr. Dev. Pathol. 12(4), 253-274 (2009).
14. Nogee LM. Genetic mechanisms of surfactant deficiency. Neonatology 85(4), 314-318 (2004).
15. Willson DF, Notter RH. The future of exogenous surfactant therapy. Respir. Care 56(9), 1369-1388 (2011).
16. Zuo YY, Veldhuizen RA, Neumann AW, Petersen NO, Possmayer F. Current perspectives in pulmonary surfactant - inhibition, enhancement and evaluation. Biochim. Biophys. Acta 1778(10), 1947-1977 (2008).
17. Gunasekara L, Schoel WM, Schürch S, Amrein MW. A comparative study of mechanisms of surfactant inhibition. Biochim. Biophys. Acta 1778(2), 433-444 (2008).
18. Kaviratna A, Banerjee R. The effect of acids on dipalmitoyl phosphatidylcholine (DPPC) monolayers and liposomes. Colloids Surf. A Physicochem. Eng. Asp. 345(1), 155-162, (2009)
19. Gunasekara L, Schürch S, Schoel WM et al. Pulmonary surfactant function is abolished by an elevated proportion of cholesterol. Biochim. Biophys. Acta 1737(1), 27-35 (2005).
20. Pallem V, Kaviratna A, Chimote G, Banerjee R. Effect of meconium on surface properties of surfactant monolayers and liposomes. Colloids Surf. A Physicochem. Eng. Asp. 370(1), 6-14 (2010).
21. Lopez-Rodriguez E, Echaide M, Cruz A, Taeusch HW, Perez-Gil J. Meconium impairs pulmonary surfactant by a combined action of cholesterol and bile acids. Biophys. J. 100(3), 646-655 (2011).
22. Mazela J, Merritt TA, Gadzinowski J, Sinha S. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases. Acta Paediatr. 95(9), 1036-1048 (2006).
23. Robertson B, Halliday HL. Principles of surfactant replacement. Biochim. Biophys. Acta 1408(2), 346-361 (1998).
24. Stevens TP, Sinkin RA. Surfactant replacement therapy. Chest 131(5), 1577-1582 (2007).
25. Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 121(2), 419-432 (2008).
26. Poulain F, Clements J. Pulmonary surfactant therapy. West. J. Med. 162(1), 43 (1995).
27. Schneider HA, Hallman M, Benirschke K, Gluck L. Human surfactant: a therapeutic trial in premature rabbits. J. Pediatr. 100(4), 619-622 (1982).
28. King RJ, Ruch J, Gikas EG, Platzker A, Creasy RK. Appearance of paoproteins of pulmonary surfactant in human amniotic fluid. J. Appl. Physiol. 39(5), 735-741 (1975).
29. Hallman M, Merritt TA, Schneider H et al. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics 71(4), 473-482 (1983).
30. Hallman M, Merritt TA, Jarvenpaa A-L et al. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J. Pediatr. 106(6), 963-969 (1985).
31. Merritt TA, Hallman M, Bloom BT et al. Prophylactic treatment of very premature infants with human surfactant. N. Engl. J. Med. 315(13), 785 (1986).
32. Merritt TA, Hallman M, Berry C et al. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J. Pediatr. 118(4), 581-594 (1991).
33. Lang MJ, Hall RT, Reddy NS, Kurth CG, Merritt TA. A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. J. Pediatr. 116(2), 295-300 (1990).
34. Vaucher YE, Merritt TA, Hallman M, Jarvenpaa A-L, Telsey AM, Jones BL. Neurodevelopmental and respiratory outcome in early childhood after human surfactant treatment. Arch. Pediatr. Adolesc. Med. 142(9), 927 (1988).
35. Speer CP, Gefeller O, Groneck P et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch. Dis. Child. Fetal Neonatal Ed. 72(1), F8-F13 (1995).
36. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur. J. Pediatr. 162(7-8), 476-480 (2003).
37. Griese M, Dietrich P, Reinhardt D. Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 152(3), 1050-1054 (1995).
38. Bloom BT, Kattwinkel J, Hall RT et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 100(1), 31-38 (1997).
39. Dhar P, Eck E, Israelachvili JN et al. Lipid-protein interactions alter line tensions and domain size distributions in lung surfactant monolayers. Biophys. J. 102(1), 56-65 (2012).
40. Alarie Y, Robillard E. Modifications of pressure-volume curves in rat lungs after inhalation of surface active extracts and agents. Physiologist 6, 128 (1963).
41. Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Microaerosol administration of synthetic b-g-dipalmitoyl-l-a-lecithin in the respiratory distress syndrome: a preliminary report. CMAJ 90(2), 55 (1964).
42. Ivey H, Roth S, Kattwinkel J, Blizzard R. Nebulization of sonicated phospholipids (PL) for treatment of respiratory distress syndrome (RDS) of infancy. Pediatr. Res. 11(4), 573-573 (1977).
43. Fujiwara T, Chida S, Watabe Y, Maeta H, Morita T, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 315(8159), 55-59 (1980).
44. Morley C, Miller N, Bangham A, Davis J. Dry artificial lung surfactant and its effect on very premature babies. Lancet 317(8211), 64-68 (1981).
45. Long W, Thompson T, Sundell H, Schumacher R, Volberg F, Guthrie R. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350- gram infants with respiratory distress syndrome. J. Pediatr. 118(4), 595-605 (1991).
46. Sáenz A, Álvarez L, Santos M et al. Beneficial effects of synthetic KL4 surfactant in experimental lung transplantation. Eur. Respir. J. 37(4), 925-932 (2011).
47. Wiswell TE, Smith RM, Katz LB et al. Bronchopulmonary segmental lavage with Surfaxin (KL4-surfactant) for acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 160(4), 1188-1195 (1999).
48. Waring A, Walther F, Gordon L et al. The role of charged amphipathic helices in the structure and function of surfactant protein B. J. Peptide Res. 66(6), 364-374 (2005).
49. Sarker M, Waring AJ, Walther FJ, Keough KM, Booth V. Structure of Mini-B, a functional fragment of surfactant protein B, in detergent micelles. Biochemistry 46(39), 11047-11056 (2007).
50. Walther FJ, Waring AJ, Hernandez-Juviel JM et al. Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs. PLoS ONE 5(1), e8672 (2010).
51. Spragg RG, Lewis JF, Walmrath H-D et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med. 351(9), 884-892 (2004).
52. Spragg RG, Lewis JF, Wurst W et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am. J. Respir. Crit. Care Med. 167(11), 1562-1566 (2003).
53. Johansson J, Some M, Linderholm B-M, Almlén A, Curstedt T, Robertson B. A synthetic surfactant based on a poly-Leu SP-C analog and phospholipids: effects on tidal volumes and lung gas volumes in ventilated immature newborn rabbits. J. Appl. Physiol. 95(5), 2055-2063 (2003).
54. Walther FJ, David-Cu R, Leung C et al. A synthetic segment of surfactant protein A: structure, in vitro surface activity, and in vivo efficacy. Pediatr. Res. 39(6), 938-946 (1996).
55. Clark H, Reid K. The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema. Arch. Dis. Child 88(11), 981-984 (2003).
56. Lu KW, Pérez-Gil J, Echaide M, Taeusch HW. Pulmonary surfactant proteins and polymer combinations reduce surfactant inhibition by serum. Biochim. Biophys. Acta 1808(10), 2366-2373 (2011).
57. Lu KW, Taeusch HW. Combined effects of polymers and KL4 peptide on surface activity of pulmonary surfactant lipids. Biochim. Biophys. Acta 1798(6), 1129-1134 (2010).
58. Hudak ML, Martin DJ, Egan EA et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 100(1), 39-50 (1997).
59. Halliday H. Overview of clinical trials comparing natural and synthetic surfactants. Neonatology 67(Suppl. 1), 32-47 (2009).
60. Bernhard W, Mottaghian J, Gebert A, Rau GA, Von Der Hardt H, Poets CF. Commercial versus native surfactants surface activity, molecular components, and the effect of calcium. Am. J. Respir. Crit. Care Med. 162(4), 1524-1533 (2000).
61. Sato A, Ikegami M. SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung. PLoS ONE 7(7), e39392 (2012).
62. Seehase M, Collins JJ, Kuypers E et al. New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs. PLoS ONE 7(10), e47631 (2012).
63. Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B. Resistance of different surfactant preparations to inactivation by meconium. Pediatr. Res. 50(1), 44-49 (2001).
64. Moya F, Sinha S, Gadzinowski J et al. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 119(6), e1361-e1370 (2007).
65. Wright J, Benson B, Williams M, Georke J, Clements J. Protein composition of rabbit alveolar surfactant subfractions. Biochim. Biophys. Acta 791(3), 320-332 (1984).
66. Magoon MW, Wright JR, Baritussio A et al. Subfractionation of lung surfactant implications for metabolism and surface activity. Biochim. Biophys. Acta 750(1), 18-31 (1983).
67. Gross NJ, Narine K. Surfactant subtypes in mice: characterization and quantitation. J. Appl. Physiol. 66(1), 342-349 (1989).
68. Manalo E, Merritt T, Amirkhanian J, Kheiter A. Characterization of surfactant subtypes of beractant and a synthetic peptide containing surfactant KL4 following surface area cycling and addition of fibrinogen. Lung 175(4), 225-233 (1997).
69. Halliday H. Surfactants: past, present and future. J. Perinatol. 28, S47-S56 (2008).
70. Phibbs RH, Tooley WH, Ballard RA et al. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics 88(1), 1-9 (1991).
71. Halpern D, Fujioka H, Takayama S, Grotberg JB. Liquid and surfactant delivery into pulmonary airways. Respir. Physiol. Neurobiol. 163(1), 222-231 (2008).
72. Cassidy K, Bull J, Glucksberg M et al. A rat lung model of instilled liquid transport in the pulmonary airways. J. Appl. Physiol. 90(5), 1955-1967 (2001).
73. Valls-I-Soler A, Fernández-Ruanova B, López-Heredia y Goya J, Etxebarría LR, Rodriguez-Soriano J, Carretero V. A randomized comparison of surfactant dosing via a dual-lumen endotracheal tube in respiratory distress syndrome. Pediatrics 101(4), e4 (1998).
74. Schermuly R, Schmehl T, Günther A, Grimminger F, Seeger W, Walmrath D. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury impact on gas exchange. Am. J. Respir. Crit. Care Med. 156(2), 445-453 (1997).
75. Shah S. Exogenous surfactant: intubated present, nebulized future? World J. Pediatr. 7(1), 11-15 (2011).
76. Gupta S, Donn SM. Novel approaches to surfactant administration. Crit. Care Res. Pract. 2012, 278483 (2012).
77. Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M. Implementation of surfactant treatment during continuous positive airway pressure. J. Perinatol. 27(7), 422-427 (2007).
78. Dani C, Corsini I, Poggi C. Risk factors for intubation-surfactant- extubation (INSURE) failure and multiple INSURE strategy in preterm infants. Early Hum. Dev. 88, S3 (2012).
79. Kribs A, Pillekamp F, Hünseler C, Vierzig A, Roth B. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age ?27 weeks). Pediatr. Anesth. 17(4), 364-369 (2007).
80. Kribs A. Early administration of surfactant in spontaneous breathing with nCPAP through a thin endotracheal catheter - an option in the treatment of RDS in ELBW infants. J. Perinatol. 29(3), 256-256 (2009).
81. Kribs A, Härtel C, Kattner E et al. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin. Padiatr. 222(1), 13-17 (2010).
82. Kribs A, Vierzig A, Hünseler C et al. Early surfactant in spontaneously breathing with nCPAP in ELBW infants - a single centre four year experience. Acta Paediatr. 97(3), 293-298 (2008).
83. Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch. Dis. Child. Fetal Neonatal Ed. 96(4), F243-F248 (2011).
84. Kattwinkel J, Robinson M, Bloom BT, Delmore P, Ferguson JE. Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J. Perinatol. 24(6), 360-365 (2004).
85. Trevisanuto D, Grazzina N, Ferrarese P, Micaglio M, Verghese C, Zanardo V. Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Neonatology 87(4), 217-220 (2005).
86. Barbosa RF, Marcatto JDO, Silva ACS, Silva YP. ProSealTM laryngeal mask airway for surfactant administration in the treatment of respiratory distress syndrome in a premature infant. Revista Brasileira de Terapia Intensiva 24(2), 207-210 (2012).
87. Roberts KD, Lampland AL, Meyers PA, Worwa CT, Plumm BJ, Mammel MC. Laryngeal mask airway for surfactant administration in a newborn animal model. Pediatr. Res. 68, 414-418 (2010).
88. Trevisanuto D, Micaglio M, Ferrarese P, Zanardo V. The laryngeal mask airway: potential applications in neonates. Arch. Dis. Child. Fetal Neonatal Ed. 89(6), F485-F489 (2004).
89. Gupta S. Laryngeal mask airway for babies: uncharted waters. Resuscitation 82, 1373-1374 (2011) .
90. Petrikovsky B, Lysikiewicz A, Markin L, Slomko Z. In utero surfactant administration to preterm human fetuses using endoscopy. Fetal Diagn. Ther. 10(2), 127-130 (2009).
91. Mazela J, Polin RA. Aerosol delivery to ventilated newborn infants: historical challenges and new directions. Eur. J. Pediatr. 170(4), 433-444 (2011).
92. Lewis JF, Ikegami M, Jobe A, Tabor B. Aerosolized surfactant treatment of preterm lambs. J. Appl. Physiol. 70(2), 869-876 (1991).
93. Lewis JF, Tabor B, Ikegami M, Jobe A, Joseph M, Absolom D. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. J. Appl. Physiol. 74(3), 1256-1264 (1993).
94. Schermuly RT, Günther A, Weissmann N et al. Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury. Am. J. Respir. Crit. Care Med. 161(1), 152-159 (2000).
95. Corcoran TE, Thomas KM, Garoff S, Tilton RD, Przybycien TM, Pilewski JM. Imaging the postdeposition dispersion of an inhaled surfactant aerosol. J. Aerosol Med. Pulm. Drug Deliv. 25(5), 290-296 (2012).
96. Dhand R. Basic techniques for aerosol delivery during mechanical ventilation. Respir. Care 49(6), 611-622 (2004).
97. Jorch G, Hartl H, Roth B et al. To the editor: surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr. Pulmonol. 24(3), 222-224 (1997).
98. Finer N. To intubate or not - that is the question: continuous positive airway pressure versus surfactant and extremely low birthweight infants. Arch. Dis. Child. Fetal Neonatal Ed. 91(6), F392-F394 (2006).
99. Berggren E, Liljedahl M, Winbladh B et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr. 89(4), 460-464 (2000).
100. Ellyett K, Broadbent R, Fawcett E, Campbell A. Surfactant aerosol treatment of respiratory distress syndrome in the spontaneously breathing premature rabbit. Pediatr. Res. 39(6), 953-957 (1996).
101. Sun Y, Yang R, Zhong J et al. Aerosolised surfactant generated by a novel noninvasive apparatus reduced acute lung injury in rats. Crit. Care 13(2), R31 (2009).
102. Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R. An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. J. Aerosol Med. Pulm. Drug Deliv. 23(5), 303-309 (2010).
103. Arzhavitina A, Steckel H. Surface active drugs significantly alter the drug output rate from medical nebulizers. Int. J. Pharm. 384(1), 128-136 (2010).
104. Lewis J, Ikegami M, Higuchi R, Jobe A, Absolom D. Nebulized vs. instilled exogenous surfactant in an adult lung injury model. J. Appl. Physiol. 71(4), 1270-1276 (1991).
105. Lewis JF, Mccaig L. Aerosolized versus instilled exogenous surfactant in a nonuniform pattern of lung injury. Am. J. Respir. Crit. Care Med. 148(5), 1187-1193 (1993).
106. Rey-Santano C, Mielgo VE, Andres L, Ruiz-Del-Yerro E, Valls-I-Soler A, Murgia X. Acute and sustained effects of aerosolized vs. bolus surfactant therapy in premature lambs with respiratory distress syndrome. Pediatr. Res. 73(5), 639-646 (2013).
107. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm. 186(1), 13-30 (1999).
108. Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically ventilated patients. Clin. Chest Med. 29(2), 277-296 (2008).
109. Ruppert C, Kuchenbuch T, Boensch M et al. Dry powder aerosolization of a recombinant surfactant protein-C-based surfactant for inhalative treatment of the acutely inflamed lung. Crit. Care Med. 38(7), 1584-1591 (2010).
110. Pohlmann G, Iwatschenko P, Koch W et al. A novel continuous powder aerosolizer (CPA) for inhalative administration of highly concentrated recombinant surfactant protein-C (rSP-C) surfactant to preterm neonates. J. Aerosol Med. Pulm. Drug Deliv. doi:10.1089/jamp.2012.0996 (2013) (Epub ahead of print).
111. Nimmo AJ, Carstairs JR, Patole SK, Whitehall J, Davidson K, Vink R. Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin. Exp. Pharmacol. Physiol. 29(8), 661-665 (2002).
112. Hughes WT, Sillos EM, Lafon S et al. Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. J. Infect. Dis. 177(4), 1046-1056 (1998).
113. Veen AVT, Mouton JW, Gommers D, Lachmann B. Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br. J. Pharmacol. 119(6), 1145-1148 (1996).
114. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am. J. Obstet. Gynecol. 168(2), 508 (1993).
115. Kari MA, Eronen M, Virtanen M et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics 93(5), 730-736 (1994).
116. Silver RK, Vyskocil C, Solomon SL, Ragin A, Neerhof MG, Farrell EE. Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered before 30 weeks' gestation. Obstet. Gynecol. 87(5, Part 1), 683-691 (1996).
117. Costa S, Zecca E, De Luca D, De Carolis MP, Romagnoli C. Efficacy of a single dose of antenatal corticosteroids on morbidity and mortality of preterm infants. Eur. J. Obstet. Gynecol. Reprod. Biol. 131(2), 154-157 (2007).
118. Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP, Milligan J. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics 76(2), 145-153 (1985).
119. Shapiro DL, Notter RH, Morin FC 3rd et al. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 76(4), 593-599 (1985).
120. Kwong MS, Egan EA, Notter RH, Shapiro DL. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics 76(4), 585-592 (1985).
121. Dunn MS, Shennan AT, Zayack D, Possmayer F. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics 87(3), 377-386 (1991).
122. Kendig JW, Notter RH, Cox C et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N. Engl. J. Med. 324(13), 865-871 (1991).
123. Kattwinkel J, Bloom BT, Delmore P et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics 92(1), 90-98 (1993).
124. Kääpä P, Seppänen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J. Pediatr. 123(1), 115-119 (1993).
125. Abbasi S, Bhutani VK, Gerdes JS. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. J. Pediatr. 122(3), 446-452 (1993).
126. Kraybill EN, Bose CL, Corbet AJ et al. Double-blind evaluation of developmental and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo. J. Pediatr. 126(5), S33-S42 (1995).
127. Corbet A, Long W, Schumacher R, Gerdes J, Cotton R. Double-blind developmental evaluation at 1-year corrected age of 597 premature infants with birth weights from 500 to 1350 grams enrolled in three placebo-controlled trials of prophylactic synthetic surfactant. J. Pediatr. 126(5), S5-S12 (1995).
128. Halliday H, Tarnow-Mordi W, Corcoran J, Patterson C. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch. Dis. Child 69(3), 276-280 (1993).
129. Verder H, Robertson B, Greisen G et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N. Engl. J. Med. 331(16), 1051-1055 (1994).
130. Verder H, Albertsen P, Ebbesen F et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 103(2), e24-e24 (1999).
131. Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks' gestation. Pediatrics 113(6), e560- e563 (2004).
132. Bloom M, Roques-Gineste M, Fries F, Lelong-Tissier M. Pulmonary haemodynamics after surfactant replacement in severe neonatal respiratory distress syndrome. Arch. Dis. Child. Fetal Neonatal Ed. 73(2), F95-F98 (1995).
133. Cochrane CG, Revak SD, Merritt TA et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 153(1), 404-410 (1996).
134. Egberts J, Brand R, Walti H, Bevilacqua G, Bréart G, Gardini F. Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 100(1), e4-e4 (1997).
135. Escobedo M, Gunkel J, Kennedy K et al. Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. J. Pediatr. 144(6), 804 (2004).
136. Femitha P, Joy R, Adhisivam B, Prasad K, Gane BD, Bhat V. Surfactant Replacement Therapy (SRT) in Respiratory distress syndrome (RDS). Curr. Pediatr. Res. 16(2), 134-136 (2012).
137. Horbar JD, Wright LL, Soll RF et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J. Pediatr. 123(5), 757-766 (1993).
138. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am. J. Perinatol. 21(03), 109-119 (2004).
139. Hudak ML, Farrell EE, Rosenberg AA et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J. Pediatr. 128(3), 396 (1996).
140. Clark RH, Auten RL, Peabody J. A comparison of the outcomes of neonates treated with two different natural surfactants. J. Pediatr. 139(6), 828-831 (2001).
141. Bloom BT, Clark RH. Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics 116(2), 392-399 (2005).
142. Ainsworth S, Beresford M, Milligan D et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet 355(9213), 1387-1392 (2000).
143. Sinha SK, Lacaze-Masmonteil T, Soler AVI et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 115(4), 1030-1038 (2005).
144. Moya FR, Gadzinowski J, Bancalari E et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 115(4), 1018-1029 (2005).
145. Ann Malloy C, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr. 94(6), 779-784 (2005).
146. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87(1), 101-107 (1991).
147. Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 92(1), 135-139 (1993).
148. Halliday HL, Speer CP, Robertson B. Treatment of severe meconium aspiration syndrome with porcine surfactant. Eur. J. Pediatr. 155(12), 1047-1051 (1996).
149. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 97(1), 48-52 (1996).
150. Mosca F, Colnaghi M, Castoldi F. Lung lavage with a saline volume similar to functional residual capacity followed by surfactant administration in newborns with severe meconium aspiration syndrome. Intensive Care Med. 22(12), 1412-1413 (1996).
151. Lam BC, Yeung C. Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics 103(5), 1014-1018 (1999).
152. Kaneko M, Watanabe J, Ueno E. Surfactant lavage and replacement in meconium aspiration syndrome with pulmonary hemorrhage. J. Perinatal Med. 29(4), 351-356 (2001).
153. Schlössser RL, Veldman A, Fischer D, Allendorf A, von Loewenich V. Lavage with exogenous surfactant in neonatal meconium aspiration syndrome. Z. Geburtshilfe Neonatol. 206(1), 15-18 (2002) .
154. Wiswell TE, Knight GR, Finer NN et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109(6), 1081-1087 (2002).
155. Salvia-Roigés M, Carbonell-Estrany X, Figueras-Aloy J, Rodríguez-Miguélez J. Efficacy of three treatment schedules in severe meconium aspiration syndrome. Acta Paediatr. 93(1), 60-65 (2004).
156. Szymankiewicz M, Gadzinowski J, Kowalska K. Pulmonary function after surfactant lung lavage followed by surfactant administration in infants with severe meconium aspiration syndrome. J. Matern. Fetal Med. 16(2), 125-130 (2004).
157. Lejeune T, Pfister RE. Surfactant lavage for extracorporeal membrane oxygenation-requiring meconium aspiration syndrome - a cheap alternative. Eur. J. Pediatr. 164(5), 331-333 (2005).
158. Collaborative Study Group for Neonatal Respiratory Diseases Chinese. Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatr. 94(7), 896-902 (2005).
159. Dargaville PA, Mills JF, Headley BM et al. Therapeutic lung lavage in the piglet model of meconium aspiration syndrome. Am. J. Respir. Crit. Care Med. 168(4), 456-463 (2003).
160. Lo C-W, Jeng M-J, Chang F-Y et al. Therapeutic lung lavage with diluted surfactant in neonates with severe meconium aspiration syndrome. J. Chin. Med. Assoc. 71(2), 103-109 (2008).
161. Gadzinowski J, Kowalska K, Vidyasagar D. Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO. J. Perinatol. 28, S56-S66 (2008).
162. Bos A, Tibboel D, Hazebroek F, Molenaar J, Lachmann B, Gommers D. Surfactant replacement therapy in high-risk congenital diaphragmatic hernia. Lancet 338(8777), 1279 (1991).
163. Lotze A, Knight GR, Anderson KD et al. Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J. Paediatr. Surg. 29(3), 407-412 (1994).
164. Glick PL, Leach CL, Besner GE et al. Pathophysiology of congenital diaphragmatic hernia III: exogenous surfactant therapy for the high-risk neonate with CDH. J. Paediatr. Surg. 27(7), 866-869 (1992).
165. Bae CW, Jang CK, Chung SJ et al. Exogenous pulmonary surfactant replacement therapy in a neonate with pulmonary hypoplasia accompaning congenital diaphragmatic hernia: a case report. J. Korean Med. Sci. 11(3), 265-270 (1996).
166. Somaschini M, Locatelli G, Salvoni L, Bellan C, Colombo A. Impact of new treatments for respiratory failure on outcome of infants with congenital diaphragmatic hernia. Eur. J. Pediatr. 158(10), 780-784 (1999).
167. Lally K, Lally P, Langham M et al. Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. J. Pediatr. Surg. 39(6), 829 (2004).
168. Van Meurs K. Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia? J. Pediatr. 145(3), 312-316 (2004).
169. Van Houten J, Long W, Mullett M et al. Pulmonary hemorrhage in premature
170. Pandit PB, Dunn MS, Colucci EA. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 95(1), 32-36 (1995).
171. Pandit PB, O'brien K, Asztalos E, Colucci E, Dunn MS. Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant. Arch. Dis. Child. Fetal Neonatal Ed. 81(1), F40-F44 (1999).
172. Amizuka T, Shimizu H, Niida Y, Ogawa Y. Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. Eur. J. Pediatr. 162(10), 697-702 (2003).
173. Walti H, Eacute, Paris-Llado J et al. Prophylactic administration of porcine-derived lung surfactant is a significant factor in reducing the odds for peri-intraventricular haemorrhage in premature infants. Neonatology 81(3), 182-187 (2002).
174. Willson DF, Thomas NJ, Markovitz BP et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury. JAMA 293(4), 470-476 (2005).
175. Willson DF, Zaritsky A, Bauman LA et al. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit. Care Med. 27(1), 188-195 (1999).
176. Willson DF, Jiao JH, Bauman LA et al. Calf's lung surfactant extract in acute hypoxemic respiratory failure in children. Crit. Care Med. 24(8), 1316-1322 (1996).
177. Pandit PB, Dunn MS, Kelly EN, Perlman M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics 95(6), 851-854 (1995).
178. Yeh TF, Lin HC, Chang CH et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 121(5), e1310-e1318 (2008).
179. Laughon M, Bose C, Moya F et al. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics 123(1), 89-96 (2009).
180. Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol. Scand. 42(7), 805-810 (1998).
181. Luchetti M, Ferrero F, Gallini C et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr. Crit. Care Med. 3(3), 261-268 (2002).
182. Herting E, Gefeller O, Land M, Van Sonderen L, Harms K, Robertson B. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 106(5), 957-964 (2000).
183. Harms K, Herting E. Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration 61(6), 348-352 (2009).
184. Fetter W, Baerts W, Bos A, Lingen RV. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr. 84(1), 14-16 (1995).
185. Lotze A, Knight GR, Martin GR et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J. Pediatr. 122(2), 261-268 (1993).
186. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J. Pediatr. 132(1), 40-47 (1998).
187. Ferrara TB, Hoekstra RE, Couser RJ et al. Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy. J. Pediatr. 124(1), 119-124 (1994).
188. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics 92(2), 191-196 (1993).
189. Pelkonen AS, Hakulinen A, Turpeinen M, Hallman M. Effect of neonatal surfactant therapy on lung function at school age in children born very preterm. Pediatr. Pulmonol. 25(3), 182-190 (1998).
190. Sleight E, Coombs R, Gibson A, Primhak R. Neonatal respiratory distress in near-term infants - consider surfactant protein B deficiency. Acta Paediatr. 86(4), 428-430 (1997).